Scientists are rapidly examining retatrutide, a promising treatment developed by Eli Lilly, as a possible step in body reduction . Unlike many existing approaches, retatrutide is a twin-action receptor targeting simultaneously GLP-1 and GIP, chemicals that impact appetite and blood glucose balan… Read More